These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19536312)

  • 1. Management of glucocorticoids-induced osteoporosis: role of teriparatide.
    Migliaccio S; Brama M; Malavolta N
    Ther Clin Risk Manag; 2009 Apr; 5(2):305-10. PubMed ID: 19536312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular etiology and treatment of glucocorticoid-induced osteoporosis.
    Peng CH; Lin WY; Yeh KT; Chen IH; Wu WT; Lin MD
    Tzu Chi Med J; 2021; 33(3):212-223. PubMed ID: 34386357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.
    Popp AW; Isenegger J; Buergi EM; Buergi U; Lippuner K
    Eur Spine J; 2006 Jul; 15(7):1035-49. PubMed ID: 16474946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of teriparatide in treatment of glucocorticoid-induced osteoporosis.
    Lau AN; Adachi JD
    Ther Clin Risk Manag; 2010 Oct; 6():497-503. PubMed ID: 21063460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.
    Whitfield JF; Morley P; Willick GE
    Treat Endocrinol; 2002; 1(3):175-90. PubMed ID: 15799210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gu Sui Bu (Drynaria fortunei J. Sm.) antagonizes glucocorticoid-induced mineralization reduction in zebrafish larvae by modulating the activity of osteoblasts and osteoclasts.
    Peng CH; Lin WY; Li CY; Dharini KK; Chang CY; Hong JT; Lin MD
    J Ethnopharmacol; 2022 Oct; 297():115565. PubMed ID: 35863613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-induced osteoporosis update.
    Adami G; Saag KG
    Curr Opin Rheumatol; 2019 Jul; 31(4):388-393. PubMed ID: 31045947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of teriparatide in osteoporotic fracture patients.
    Collinge C; Favela J
    Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of corticosteroids on bone metabolism: a review.
    Mitra R
    PM R; 2011 May; 3(5):466-71; quiz 471. PubMed ID: 21570035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
    Tanaka I; Tanaka Y; Soen S; Oshima H
    J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of glucocorticoid action in bone.
    Canalis E; Delany AM
    Ann N Y Acad Sci; 2002 Jun; 966():73-81. PubMed ID: 12114261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte.
    Wang T; Yu X; He C
    Curr Drug Targets; 2019; 20(1):1-15. PubMed ID: 29618305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone temporal effects on bone formation and resorption.
    Kroll MH
    Bull Math Biol; 2000 Jan; 62(1):163-88. PubMed ID: 10824426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid-induced osteoporosis in men.
    Adler RA; Hochberg MC
    J Endocrinol Invest; 2011 Jun; 34(6):481-4. PubMed ID: 21623147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced osteoporosis: management update.
    Adler RA
    Curr Osteoporos Rep; 2010 Mar; 8(1):10-4. PubMed ID: 20425085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
    Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
    Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.
    Mazziotti G; Giustina A; Canalis E; Bilezikian JP
    Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1404-12. PubMed ID: 18209880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.